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Abstract
A novel 96-microwell-based spectrophotometric assay has been developed and validated for determination of
olmesartan medoxomil (OLM) in tablets. The formation of a colored charge-transfer (CT) complex between OLM as
a n-electron donor and 2, 5-dichloro-3, 6-dihydroxy-1, 4-benzoquinone (p-chloranilic acid, pCA) as a π-electron
acceptor was investigated, for the first time, and employed as a basis in the development of the proposed assay.
The proposed assay was carried out in 96-microwell plates. The absorbance of the colored-CT complex was
measured at 490 nm by microwell-plate absorbance reader. The optimum conditions of the reaction and the
analytical procedures of the assay were established. Under the optimum conditions, linear relationship with good
correlation coefficient was found between the absorbance and the concentration of OLM in the range of 1-200 μg
ml-1. The limits of detection and quantitation were 0.3 and 1 μg ml-1, respectively. No interference was observed
from the additives that are present in the pharmaceutical formulation or from hydrochlorothiazide and amlodipine
that are co-formulated with OLM in some formulations. The assay was successfully applied to the analysis of OLM
in tablets with good accuracy and precision. The assay described herein has great practical value in the routine
analysis of OLM in quality control laboratories, as it has high throughput property, consumes minimum volume of
organic solvent thus it offers the reduction in the exposures of the analysts to the toxic effects of organic solvents,
and reduction in the analysis cost by 50-fold. Although the proposed assay was validated for OLM, however, the
same methodology could be used for any electron-donating analyte for which a CT reaction can be performed.
Keywords: Olmesartan medoxomil, Charge-transfer reaction, Spectrophotometry, Microwell-based assay, High
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Background
Olmesartan medoxomil (OLM); (5-methyl-2-oxo-2H-
1,3-dioxol-4-yl)methyl 4-(2-hydroxy-propan-2-yl)-2-pro-
pyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}
methyl)-1H-imidazole-5-carboxylate (Figure 1), is the
newest member of non-peptide angiotensin II receptor
antagonists used worldwide in the treatment of hyper-
tension. It is an ester prodrug, which is completely and
rapidly hydrolyzed to the active acid form, olmesartan.
OLM exerts its action mainly via a selective blockade
action on AT1 receptors and the consequent reduced
pressor effect of angiotensin II [1,2]. OLM may be used
alone or in combination with other antihypertensive
agents. The FDA has determined that the benefits of
OLM continue to outweigh its potential risks when used
for the treatment of patients with high blood pressure
according to the drug label. OLM is also used by some
people who are treated with an unproven therapy for
autoimmune diseases known as the Marshall Protocol.
OLM has not yet been officially described in any phar-
macopoeia. A literature survey revealed that several ana-
lytical methods were reported for its determination.
These methods include high-performance thin-layer
chromatography [3], liquid chromatography [3-9], and
capillary zone electrophoresis [10]. These methods were
not simple to perform, time-consuming, and utilize
expensive instruments that are not available in most
quality control laboratories. In general, spectrophotome-
try is the most widely used technique in pharmaceutical
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analysis because of its inherent simplicity and wide
availability in most quality control laboratories [11].
However, few spectrophotometric methods have been
reported for the analysis of OLM in its pharmaceutical
tablets [12-15]. Unfortunately, these methods suffer
from major drawbacks such as decreased selectivity due
to measuring the native light absorption of OLM in the
blue-shifted ultraviolet region, which might be subjected
to interferences [12-14]. Besides the tedious liquid-liquid
extraction procedures using large volumes of organic
solvents in the methods based on formation of ion-pair
associates [15]. Therefore, the development of a new
alternative spectrophotometric method for determina-
tion of OLM in pharmaceutical formulations is very
essential.
The molecular interactions between the electron-
donating pharmaceutical compounds and electron-
accepting reagents are generally associated with the for-
mation of intensely colored CT complexes, which
usually absorb radiations in the visible region. The rapid
formation of these complexes leads to their widespread
utility in the development of visible spectrophotometric
methods for analysis of many pharmaceutical com-
pounds [16-20]. Literature survey revealed that the CT
reaction of OLM has not been investigated yet. This fact
promoted our interest in employment of the CT-reac-
tion as a basis for the development of a new spectro-
photometric method for determination of OLM.
However, all the conventional CT-based spectrophoto-
metric methods that have been reported so far are not
automated and consequently their throughput is low,
thus their applications in pharmaceutical quality control
laboratories are limited. Moreover, these methods suffer
from the consumption of large volumes of organic sol-
vents, which leads to high analysis cost, and more
importantly, the incidence of exposure of the analysts to
the toxic effects of the organic solvents [21-25].
For these reasons, the present study is devoted to
investigate the CT reaction of OLM, and its employ-
ment in the development of a novel non-conventional
spectrophotometric assay with high analysis throughput
and can reduce the consumption of organic solvents in
the determination of OLM in tablets.
Experimental
Apparatus
Microwell-plate absorbance reader (ELx 808, Bio-Tek
Instruments Inc. Winooski, USA) was used for all the
measurements in 96-microwell plates. UV-1601 PC (Shi-
madzu, Kyoto, Japan) ultraviolet-visible spectrophot-
ometer with matched 1 cm quartz cells was used for
recording the absorption spectra. 96-Microwell plates
were a product of Corning/Costar Inc. (Cambridge,
USA). Finnpipette adjustable 8-channel-pipette was
obtained from Sigma Chemical Co. (St. Louis, MO,
USA).
Chemicals and tablets
OLM was obtained from AK Scientific Inc. (California,
USA). Amlodipine besylate and hydrochlorothiazide
were obtained from Sigma Chemical Co. (St. Louis,
USA). pCA (BDH Chemicals, Poole, UK) was 0.5% (w/v)
in acetonitrile and it was prepared fresh daily. Olmetec®
tablets (SAJA Pharmaceuticals, Jeddah, Saudi Arabia)
labeled to contain 20 mg OLM were obtained from the
local market.
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Figure 1 The chemical structure of olmesartan medoxomil
(OLM) and the co-formulated drugs.
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Preparation of standard and tablet solutions
Preparation of stock standard solutions
Into a 5-ml calibrated flask, 10 mg of OLM was accu-
rately weighed, dissolved in 2 ml methanol, and com-
pleted to volume with the same solvent. This stock
solution was diluted with methanol to obtain the suita-
ble concentrations that lie in the linear range of the
assay.
Preparation of tablet sample solutions
Twenty tablets were weighed and finely powdered. A
quantity of the powder equivalent to 20 mg of OLM
was transferred into a 10-ml calibrated flask, dissolved
in 4 ml methanol, swirled and sonicated for 5 min, com-
pleted to volume with the methanol, shaken well for 15
min, and filtered. The first portion of the filtrate was
rejected, and a measured volume of the filtrate was
diluted quantitatively with methanol to yield the suitable
concentrations that lie in the linear range of the assay.
General analytical procedure
Accurately measured aliquots (100 μl) of the standard
or sample solution containing varying amounts of OLM
(1-200 μg ml-1) were transferred into wells of 96-micro-
well assay plates. One hundred microliters of pCA solu-
tion (0.5%, w/v) was added, and the reaction was
allowed to proceed at room temperature (25 ± 1°C) for
5 min. The absorbances of the resulting solutions were
measured at 490 nm by the microwell-plate reader.
Blank wells were treated similarly except 100 μl of
methanol was used instead of sample, and the absor-
bances of the blank wells were subtracted from those of
the other wells.
Determination of molar ratio
The Job’s method of continuous variation [26] was
employed. Master equimolar solutions (2 × 10-3 M) of
each of OLM and pCA were prepared. Series of 200 μl
portions of the master solutions of OLM with pCA were
made up comprising different complementary ratios
(0:10, 1:9, ........., 9:1, 10:0, inclusive) in each well of the
96-microwell assay plate. The reaction was allowed to
proceed at room temperature (25 ± 1°C) for 5 min. The
absorbances of the developed colors were measured at
490 nm by the microwell-plate reader against blank
wells treated similarly except methanol was used instead
of OLM sample. The measured absorbances were
plotted as a function of OLM mole fraction. The gener-
ated plot was used for determination the molar ration of
OLM:pCA.
Molecular modeling for the CT complex of OLM with pCA
The molecular modeling for the CT complex was per-
formed by using CS Chem3D Ultra, version 9 (Cam-
bridge Soft Corporation, Cambridge, MA, USA)
implemented with molecular orbital computations soft-
ware (MOPAC), and molecular dynamics computations
software (MM2).
Results and discussion
Strategy for assay development and its design
In the present study, OLM was selected based on its
therapeutic importance, clinical success, and the
expected electron-donating ability. Previous studies
involving CT reactions with polyhalo-/polycyanoquinone
electron n-acceptors revealed that pCA is one of the
most efficient reagents in terms of its reactivity [18,27].
Furthermore, its CT reaction with electron-donating
analytes is instantaneous [18,19]. For these reasons, pCA
was used as electron acceptor in the development of the
proposed assay. The proposed assay was designed to
employ 96-microwell assay plate as the CT reaction was
carried out in microwells of the assay plate (200-μl reac-
tion volume). The solutions were dispensed by 8-chan-
nel pipette, and the absorbances of the colored CT
complex were measured by 96-microwell-plate absor-
bance reader. The 96-microwell design of the proposed
assay was based on the previous success of Darwish et
al [28] in the utility of this design for determination of
some other pharmaceuticals.
Reaction and spectral characteristics
The interaction of OLM with pCA was allowed to pro-
ceed at room temperature, and the absorption spectrum
of the produced chromogen was recorded on an ultra-
violet-visible spectrophotometer (UV-1601 PC (Shi-
madzu, Kyoto, Japan). OLM gave red colored
chromogen showing absorption maximum at 520 nm.
This band was attributed to the formation of the radical
anion pCA- [29], which was probably formed by the dis-
sociation of an original donor-acceptor (D-A) complex:
D + A (D− A)
complex
polar
solvent D·+ + A.−
radical ions
pCA exists in three ionic forms, the neutral yellow-
orange H2A at very low pH, the dark purple HA
– which
is stable at pH = 3 and a pale violet A2–, which is stable
at high pH; these transformations are illustrated in the
following scheme:
H2A H+ + HA - (violet),
HA -  H+ + A2 - (colorless).
Since the interaction of OLM with pCA in acetonitrile
gave a violet product, it might be concluded that HA-
was the form of pCA involved in the reaction described
herein.
Optimization of experimental conditions
The optimization of experimental conditions affecting
the reaction in the 96-well format was investigated by
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altering each reaction variable in a turn while keeping
the others constant. Although, the OLM-pCA complex
exhibited maximum absorption peak at 520 nm, how-
ever the measurements were carried out at 490 nm, as
this is the closest wavelength filter available in the plate
reader. The results of variations in the pCA concentra-
tions indicated that 100 μl of 0.5% (w/v) was the opti-
mum pCA concentration, as this concentration gave the
highest absorbances. Previous studies [30] demonstrated
that the interaction of electron-donors with pCA in
polar solvents (e.g. methanol and acetonitrile) produces
CT complexes with molar absorptivity values higher
than those produced in non-polar solvents (e.g. chloro-
form). Different polar solvents were tested as a solvent
for preparing pCA; these solvents were methanol, etha-
nol, 1-propanol, 1-butanol, and acetonitrile. Acetonitrile
offered the highest sensitivity, therefore it was selected.
The optimum reaction time was determined by moni-
toring the color development in the microwells at room
temperature (25 ± 1°C). Complete color development
was attained instantaneously, however for higher preci-
sion readings, the reaction was allowed to proceed for 5
min. The developed color remained stable at room tem-
perature for at least a further 30 min. A summary for
the optimum conditions is given in Table 1.
Molar ratio of the reaction, molecular modeling, and
proposing the site of interaction
Job’s method of continuous variation [26] was used for
determining the molar ratio of OLM to pCA. From the
obtained Job’s plot, it was concluded that the OLM:pCA
ratio is 1:1. This indicated that only one site of interac-
tion was involved in the formation of the colored CT
complex in spite of the presence of more than one pos-
sible electron-donating sites in OLM structure (e.g. OH
of the hydroxypropane-2-yl group and the nitrogen
atoms of the tetrazole ring). For investigating the site of
interaction and postulate the reaction mechanism, mod-
eling for the CT complex was performed. OLM and
pCA were energy-minimized alone and both together. It
was found that the electron densities in OLM molecule
that are located on the oxygen atom of the OH of the
hydroxypropane-2-yl group, oxygen atom of the ester
linkage, and nitrogen atoms of the tetrazole are compar-
able (-0.39428, -0.33456, and -0.33085). As well, it was
found that pCA moves toward the tetrazole moiety of
OLM to form the CT complex (Figure 2). These facts,
taking the molar ratio in account, confirmed that only
the tetrazole is involved in the complex formation. The
other anticipated centers did not contribute in the CT
reaction, probably due the steric hindrance effect of the
OLM molecules [31].
Validation of the proposed assay
Linearity and sensitivity
Under the above mentioned optimum reaction condi-
tions, the calibration curve for the analysis of OLM by
the proposed assay was constructed by plotting the
absorbances as a function of the corresponding concen-
trations. The regression equation for the results was
derived using the least-squares method. Beer’s law plot
(10-points) was linear in the range of 1 - 200 μg ml-1.
The calibration equation was: A = -0.0335 + 0.0827 C (r
= 0.9951), where A, C and r are the absorbance, concen-
tration of OLM and correlation coefficient, respectively.
The limits of detection (LOD) and quantitation (LOQ)
were determined [32] using the formula: LOD or LOQ
= SDa/b, where  = 3 for LOD and 10 for LOQ, SDa
is the standard deviation of the intercept, and b is the
slope. The LOD and LOQ values were 0.3 and 1 μg ml-
1, respectively. The quantitative parameters of the pro-
posed assay are given in Table 2.
Accuracy and precision
Accuracy of the proposed assay was assessed by analyti-
cal recovery studies. Recovery was determined by the
standard addition method. Known amounts of OLM
were added to pre-determined drug-containing tablets,
and then determined by the proposed assay. The mean
analytical recovery was calculated and found to be 97.6-
99.7 ± 0.5-1.5% indicating the accuracy of the proposed
assay.
The precisions of the proposed assay were determined
on samples of drug solutions at three concentration
levels for each drug (Table 3) by analyzing 5 replicates
of each sample as a batch in a single assay run. The
relative standard deviations (RSD) did not exceed 2%
(Table 3) proving the high precision of the assay for the
routine application in quality control laboratories.
This high level of precision was attributed to the accu-
racy of the volumes that have been concomitantly dis-
pensed in the microwells by multi-channel pipettes, and
completeness of the reaction the small volume (200 μl).
Selectivity
The proposed assay has the advantages that the mea-
surements are performed in the visible region, away
from the UV-absorbing interfering substances that
Table 1 Optimum conditions for the charge-transfer
reaction of OLM with PCA
Condition Studied range Optimum
pCA conc. (%, w/v) 0.1 - 2 0.5
Solvent Differenta Acetonitrile
Reaction time (min) 0 - 30 5
Temperature (°C) 25 - 60 25
lmax (nm) 400 - 600 520
b
a Solvents tested: methanol, ethanol, 1-propanol, 1-butanol, and acetonitrile.
b Measurements were carried out at 490 nm.
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might be co-extracted from dosage forms that contain
OLM. The interference from the congenital drugs that
is co-formulated with OLM in some dosage forms was
studied. These drugs were amlodipine besylate [33-35]
hydrochlorothaizde [35,36] and the chemical structures
of these drugs are given in Figure 1. Potential interfer-
ences of these drugs were studied in a ratio which is
normally present in their combined dosage forms. No
interferences from these drugs were found with OLM in
the proposed assay.
This specificity of the CT reaction for OLM was
attributed to its basic character, which allows the CT,
rather than hydrochlorothaizde, that does not have suffi-
cient basicity to achieve CT reaction (pKa = 7.9) [37].
Although, amlodipine has basic character, however it is
co-formulated with OLM as besylate salt that did not
show any ability for CT reaction with pCA under the
proposed assay conditions. As well, no interference was
observed from the excipients with the proposed assay as
indicated from the obtained good recovery (mentioned
above). The absence of interference from the excipients,
even though they contain basic component(s) was attrib-
uted to the extraction of the OLM tablets prior to the
analysis with methanol in which the excipients do not
dissolve.
Application of the proposed assay in the analysis of OLM
tablets
The commercially available tablets of OLM (Olmetec®
tablets) was subjected to the analysis by the proposed
and reported methods [4], and the obtained results were
then statistically compared with each other. The mean
percentage recovery, relative to the labeled amounts,
obtained by the proposed assay was 99.8 ± 1.24% (Table
4). Values for t- and F-tests were calculated and found
to be 2.35 and 2.13, respectively. These calculated t- and
CT complex of OLM with pCA  
OLMpCA  
Figure 2 Energy-minimized CT complex of OLM with pCA.
Table 2 Quantitative parameters for the analysis of OLM
by the proposed assay
Parameter Value




LOD (μg ml-1) 0.3
LOQ (μg ml-1) 1
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F-values were lower than the tabulated ones (2.78 and
9.39, respectively) indicating that there was no signifi-
cant differences between the both the proposed and the
reported assays at 95% confidence level in terms their
accuracy and precision.
Conclusion
The present study described the development and vali-
dation of a novel microwell-based spectrophotometric
assay for the determination of OLM based on its CT
reaction with pCA reagent. In this assay, the CT reac-
tion was carried out in 96-microwell plates (200-μl reac-
tion volume) instead of the conventional volumetric
flasks (10,000-μl volume). The absorbances were mea-
sured by microwell-plate reader instead of the conven-
tional spectrophotometer. The assay described herein
offered the following advantages:
- Reduction in the consumption of organic solvents in
the CT-based spectrophotometric analysis, accordingly
reduction in the exposures of the analysts to the toxic
effects of organic solvents.
- Reduction in the analysis cost by 50-folds which can
be reflected on the price for the finished dosage forms,
thus it can reduce the expenses for the medications.
- Providing a high throughput analytical methodology
that can facilitate the processing of large number of
samples in a relatively short time. This property was
attributed to the use of multi-channel pipettes for effi-
cient dispensing of the solutions, carrying out the analy-
tical reaction in 96-well plates (as reaction vessels), and
measuring the color signals in the 96 wells at ~ 30 sec-
onds by the plate reader.
- Although the proposed assay was developed and
validated for OLM, however, it is also anticipated that
the same methodology could be used for essentially any
analyte that can exhibit CT reaction.
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